Vitiligo associated with BCG-methanol extraction residue in malignant melanoma. Report of a case.
A pronounced vitiliginous reaction developed at the sites of MER/BCG injections given as an adjuvant immunotherapy to a patient with malignant melanoma. To our knowledge, this is the third report on patients exhibiting vitiligo apparently induced by immunotherapy and the first in association with MER. This association may be a sign for an antimelanocytic effect and may offer a further confirmation for the autoimmune nature of vitiligo.
D000328:Adult; D001500:BCG Vaccine / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D005260:Female; D006801:Humans; D007271:Injections, Intradermal; D008545:Melanoma / Q000188:drug therapy*; D000432:Methanol / Q000008:administration & dosage; D014820:Vitiligo / Q000209:etiology* / Q000276:immunology
D001500:BCG Vaccine; D000432:Methanol